Sugar tools for COVID-19 vaccine and drug development
Glycans are densely covering both the virus COV-2A spike protein and the human ACE2 receptor – so both the Key and the Lock are heavily sugar coated!
Glycans are likely to play major roles for the COV-2A virus infection and immunity, and studies of the virus interaction with the ACE-2 receptor and S1 glycoprotein vaccines need to consider the glycans.
GlycoDisplay has developed mammalian cell systems to display and produce any glycoprotein with different custom designed glycans. GlycoDIsplay now offers these services and tools for urgent COVID-19 research and drug development, including:
- Production of glycovariants of COV-2A Spike protein
- Production of glycovariants of ACE2 receptor
The proteins may be produced in different cell lines and formats to most naturally reflect the COVID-19 infectivity process and thus readily support Vaccine development (spike protein) and development of new drugs that blocks binding of virus to the ACE2 receptor.
Please contact us for access to these tools under custom service contract
Figure from Nature579, 459-461 (2020) Nature (Xiong et al J.Virol.)